Data Presented From European Study of Eximo Medical’s B-Laser Atherectomy Catheter


November 8, 2018—John R. Laird Jr, MD, presented the European study data on Eximo Medical’s B-Laser atherectomy catheter at VIVA 2018, the Vascular Interventional Advances annual conference held November 5–8 in Las Vegas, Nevada.

Researchers set out to evaluate the B-Laser catheter for treatment of infrainguinal peripheral artery disease. In total, 53 lesions treated with the B-Laser were evaluated in 50 patients (38 men; mean age, 64 years) with Rutherford class 2 to 4 peripheral artery disease.

Calcification was seen in 88% of lesions and was graded as mild (27%) or moderate/severe (61%). Forty-three (78%) lesions were chronic total occlusions. Average lesion length was 7.4 cm; 45 of 53 (84.9%) lesions were in the superficial femoral artery, and eight (15.1%) were in the superficial femoral/popliteal artery, popli­teal artery, and tibioperoneal trunk.

Clinical success was achieved in all 53 lesions. Researchers reported there were no perioperative device-related perforations, dissections, or distal embo­lizations, nor any other device-related complica­tions.

Core lab evaluation of baseline stenosis, post–B-Laser and residual stenosis, and average reduction in residual stenosis after B-Laser use were 93.6% ± 13.6%, 58.7% ± 15.1%, and 35.04% ± 14.78%, respectively. Only two (2/46 [4.3%]) target lesion revascularizations were noted at 1-year follow-up.;

Based on these results, researchers concluded the B-Laser catheter is a promising technology for atherectomy of complex heterogeneous lesions and noted that additional research is ongoing.

According to the VIVA announcement, the B-Laser catheter is an atherectomy device that uses an array of optical fibers transmitting short (approximately 10 ns) pulses of 355-nm waves (small solid-state Nd:YAG laser) surrounded by a blunt blade. The catheter has a threefold higher affinity for ablation of fibrotic mate­rial than endothelium, is indifferent to contrast media pres­ence, has aspiration (with the 2- and 2.35-mm catheters) and off-centering mechanisms (with the 2.35-mm catheter), and works efficiently in all types of lesions, including calcifi­cation.

Eximo Medical received FDA 510(k) clearance for the B-Laster atherectomy for use in peripheral artery disease in October.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.